Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

Last Close
Jan 08  •  04:00PM ET
0.8500
Dollar change
+0.0097
Percentage change
1.15
%
Index- P/E- EPS (ttm)-3.68 Insider Own8.10% Shs Outstand12.73M Perf Week-13.89%
Market Cap10.99M Forward P/E- EPS next Y-1.73 Insider Trans0.00% Shs Float11.88M Perf Month-37.04%
Enterprise Value32.54M PEG- EPS next Q-0.44 Inst Own35.69% Short Float0.90% Perf Quarter-47.53%
Income-36.56M P/S0.94 EPS this Y63.37% Inst Trans2.38% Short Ratio0.29 Perf Half Y-55.96%
Sales11.65M P/B- EPS next Y31.43% ROA-104.28% Short Interest0.11M Perf YTD-13.89%
Book/sh-1.15 P/C1.21 EPS next 5Y46.48% ROE-2951.24% 52W High3.65 -76.71% Perf Year-75.92%
Cash/sh0.70 P/FCF- EPS past 3/5Y11.49% 18.70% ROIC-472.97% 52W Low0.77 10.25% Perf 3Y-93.10%
Dividend Est.- EV/EBITDA- Sales past 3/5Y0.80% 1.75% Gross Margin98.19% Volatility8.77% 8.03% Perf 5Y-99.48%
Dividend TTM- EV/Sales2.79 EPS Y/Y TTM52.92% Oper. Margin-294.64% ATR (14)0.09 Perf 10Y-99.71%
Dividend Ex-Date- Quick Ratio0.70 Sales Y/Y TTM13.56% Profit Margin-313.79% RSI (14)25.85 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio0.70 EPS Q/Q70.98% SMA20-20.51% Beta3.07 Target Price14.00
Payout- Debt/Eq- Sales Q/Q8.36% SMA50-29.82% Rel Volume4.07 Prev Close0.84
Employees34 LT Debt/Eq- EarningsNov 06 AMC SMA200-49.25% Avg Volume366.13K Price0.85
IPOAug 01, 2000 Option/ShortNo / No EPS/Sales Surpr.15.22% 11.05% Trades Volume1,454,194 Change1.15%
Date Action Analyst Rating Change Price Target Change
May-19-25Resumed H.C. Wainwright Buy $17
Nov-17-23Initiated Truist Buy $26
Apr-04-22Downgrade Raymond James Outperform → Mkt Perform
Oct-13-21Initiated Raymond James Outperform $15
Mar-25-21Initiated B. Riley Securities Buy $19
Jul-29-20Initiated Laidlaw Buy $5
Jul-17-20Initiated Cantor Fitzgerald Overweight $4
Oct-24-17Initiated Guggenheim Buy $7
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy $3
Nov-09-15Reiterated ROTH Capital Buy $6 → $5
Jan-07-26 08:45AM
Dec-09-25 08:00AM
Nov-14-25 09:26AM
Nov-07-25 12:02AM
Nov-06-25 05:10PM
04:08PM Loading…
04:08PM
04:00PM
Oct-30-25 04:00PM
Oct-03-25 04:00PM
Sep-02-25 10:43AM
Aug-06-25 11:00AM
Aug-05-25 09:10AM
08:08AM
08:00AM
Aug-04-25 10:13AM
08:30AM Loading…
Jul-29-25 08:30AM
Jul-02-25 08:32AM
May-07-25 03:07AM
May-06-25 06:16PM
09:05AM
08:13AM
08:00AM
May-05-25 10:26AM
May-01-25 10:01AM
Apr-29-25 08:00AM
Apr-12-25 11:00AM
Apr-02-25 04:05PM
Apr-01-25 03:01AM
01:42AM
Mar-31-25 09:59AM
08:16AM Loading…
08:16AM
08:00AM
Mar-28-25 04:07PM
Dec-10-24 08:00AM
Nov-15-24 02:37AM
02:07AM
Nov-14-24 09:10AM
08:09AM
08:00AM
Nov-13-24 07:31AM
Nov-07-24 08:00AM
Nov-02-24 11:20AM
Oct-29-24 06:04AM
Oct-09-24 03:42PM
Sep-23-24 08:30AM
Sep-17-24 07:30AM
Sep-04-24 08:00AM
Aug-01-24 09:10AM
08:07AM
08:00AM
Jul-25-24 08:00AM
Jul-10-24 07:30AM
Jul-09-24 12:00PM
Jul-08-24 07:30AM
May-14-24 04:00PM
May-10-24 08:00AM
May-08-24 11:39AM
May-07-24 12:53PM
08:08AM
08:00AM
Apr-30-24 08:00AM
Apr-05-24 08:43AM
07:30AM
Apr-04-24 07:30AM
Feb-09-24 10:10AM
Feb-08-24 08:11AM
08:00AM
Feb-01-24 08:00AM
Jan-05-24 08:00AM
Dec-12-23 08:00AM
Dec-11-23 08:00AM
Dec-06-23 08:00AM
Dec-05-23 08:00AM
Nov-03-23 10:26AM
06:03AM
Nov-02-23 08:19AM
08:00AM
Oct-30-23 10:00AM
Oct-26-23 08:30AM
Oct-06-23 08:56AM
Sep-22-23 03:15AM
Sep-12-23 08:00AM
Sep-06-23 08:13AM
Aug-05-23 05:57AM
Aug-03-23 05:45PM
04:43PM
04:01PM
Jul-27-23 06:25PM
Jul-06-23 08:01AM
08:00AM
Jun-30-23 06:50AM
Jun-06-23 06:54AM
May-15-23 11:33AM
May-05-23 07:30AM
May-04-23 05:45PM
04:26PM
04:01PM
Apr-27-23 04:01PM
Apr-17-23 08:12AM
Apr-05-23 08:13PM
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.